Quantcast

Industry news that matters to you.  Learn more

Biocartis and Amgen Sign a RAS Biomarker Testing Collaboration in Europe

Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), recently announced the signing of a new collaboration agreement with Amgen, a leading biotechnology company. The new agreement, which builds on the existing collaboration between both companies announced on 3 February 20161, aims at accelerating access to RAS biomarker information in up to 10 European countries.

Biocartis and Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing

Biocartis, an innovative molecular diagnostics company, recently announced that Biocartis has signed a collaboration agreement with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be developed on Biocartis’ innovative, fully automated molecular diagnostics system, Idylla™, which is designed to offer accurate and reliable molecular information from virtually any biological sample in virtually any setting. The new test aims to support clinical practice in performing integrated liquid biopsy RAS biomarker tests, independently of the laboratories’ volume of testing or level of expertise.

Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test

Biocartis and VIB recently announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.